Translating cutting-edge academic research into market-ready innovations requires not only capital but also strategic guidance and a deep understanding of scientific risk. In this presentation, Dr. Martin Raditsch, General Partner of CARMA FUND Management GmbH, will outline the fund’s mission and investment strategy as one of Europe’s pioneering early-stage and project-focused life-science investors. CARMA Fund targets very early translational stages, often before company formation, providing tailored financing to bridge the gap between academic proof-of-concept and venture readiness. Dr. Raditsch will share insights into the fund’s current portfolio activities, including how CARMA works closely with universities, technology transfer offices, and scientific founders to de-risk projects, validate technologies, and accelerate time to market. He will discuss key investment criteria, risk-mitigation approaches, and the unique project funding model that enables CARMA to identify transformative biomedical innovations while operating trend-agnostically and counter-cyclically. Participants will gain a clear understanding of how CARMA Fund structures investments, selects projects with disruptive potential, and creates value for both researchers and investors in a rapidly evolving life-science ecosystem.
